Eurofins Viracor announces the launch of cPass™ Coronavirus SARS-CoV-2 Neutralizing Antibody Testing

Monday, April 05, 2021

Eurofins Viracor, a leader in infectious disease testing for over 35 years, announces the launch of cPass™ Coronavirus SARS-CoV-2 Neutralizing Antibody test. This test aids in the identification of recent or prior infection for SARS-CoV-2, the virus that causes COVID-19. The ELISA-based methodology detects neutralizing antibodies to the receptor binding domain (RBD) of the spike (S) protein. This test has been authorized by the FDA under an Emergency Use Authorization (EUA) for use by laboratories certified under CLIA to perform high complexity tests.

This test can identify if a person has produced neutralizing antibodies in response to a COVID-19 infection or inoculation with a vaccine. Neutralizing antibodies are a subset of binding antibodies capable of blocking cellular entry SARS-CoV-2. The cPass™ Coronavirus SARS-CoV-2 Neutralizing Antibody test is specific to SARS-CoV-2 neutralizing antibodies.

As one of the first commercial labs to deliver COVID-19 testing, Viracor has launched testing to aid in the detection of SARS-CoV-2. The cPass™ Coronavirus SARS-CoV-2 Neutralizing Antibody test joins the robust menu of RT-PCR, IgG and, IgM testing to help identify active or prior COVID-19 cases. Viracor's SARS-CoV-2 RT-PCR assay offers the best sensitivity of the 117 laboratories that have submitted results to FDA's SARS-CoV-2 Reference Panel, with a limit of detection of 180 NAAT Detectable Units/mL1.

Viracor continues to invest in innovation with the upcoming launch of an immune response assay to evaluate Coronavirus SARS-CoV-2-specific cell mediated immunity of CD4+ and CD8+ T Cells by flow cytometry and intracellular cytokine staining.

1 https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data

To learn more, please visit:  https://www.viracor-eurofins.com/about-us/newsroom/news-items/eurofins-viracor-announces-the-launch-of-cpass-coronavirus-sars-cov-2-neutralizing-antibody-testing/?utm_source=PR&utm_medium=Link&utm_campaign=COVID_nAb

About Viracor
Eurofins Viracor has over 30 years of diagnostic expertise in infectious disease, immunology and allergy testing for immunocompromised and critical patients. Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.viracor-eurofins.com/clinical-diagnostics/.

About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With over 50,000 staff across a network of more than 800 laboratories in over 50 countries, Eurofins' companies offer a portfolio of over 200,000 analytical methods.Eurofins Shares are listed on Euronext Paris Stock Exchange.

Latest Issue
Get instant
access to our latest e-book